ArticleArchives of toxicology2026
Use of matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to visualize and support interpretation of toxic effects of 4-hydroxyphenylpyruvate dioxygenase inhibitors in rat tissues.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MALDI mass spectrometry imaging across spatial scales in toxicology: tissue evidence, cellular heterogeneity, and emerging single-cell opportunities.Analytical and bioanalytical chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
4-Hydroxyphenylpyruvate dioxygenase inhibitors (HPPDi) are mainly used as herbicides and for therapeutic use in genetic diseases of tyrosine catabolism. Their primary mechanism of action is the inhibition of the second enzyme of tyrosine catabolism, leading to an accumulation of this amino acid in blood and tissues. In this work, rats were administered diets with 1 ppm, 2 ppm, and 10 ppm of HPPD-inhibitor BCS-CR75391 for up to 28 days, and tyrosine levels were measured in blood and in selected organs using mass spectrometry combined with gas or liquid chromatography and analyzed spatially using mass spectrometry imaging (MSI). The highest tyrosine accumulation was recorded in the pancreas, followed by the eyes and the thyroid gland. Metabolomic profiling showed that other amino acids and metabolites of the citric acid cycle were influenced by the treatment. A metabolic adaptation was observed in the liver and kidney 28 days after the treatment, but not in other tissues analyzed. MSI of the thyroid gland seems to reveal an uneven accumulation of tyrosine in the tissue of rats following treatment with BCS-CR75391. Most interestingly, a significant accumulation of iodide was detected in the thyroid gland of all rats treated with the 4-hydroxyphenylpyruvate dioxygenase inhibitor. In addition, induced high tyrosine levels by a tyrosine-rich diet also provoke the accumulation of iodide in the thyroid gland. While the toxicological impact of these results needs to be further investigated, these results support the use of MSI as an innovative and powerful tool to support toxicological assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.